Navicixizumab

Navicixizumab is an investigational bi-specific antibody that inhibits the activity of both vascular endothelial growth factor A (VEGF-A) and delta-like ligand 4 (DLL4), two pathways identified in playing a role in tumor progression. The concurrent inhibition of VEGF-A and DLL4 with navicixizumab mediates inhibited tumor angiogenesis and may also lead to enhanced activity of concurrently administered cancer therapeutics.
Navicixizumab

Navicixizumab is an investigational bi-specific antibody that inhibits the activity of both vascular endothelial growth factor A (VEGF-A) and delta-like ligand 4 (DLL4), two pathways identified in playing a role in tumor progression. The concurrent inhibition of VEGF-A and DLL4 with navicixizumab mediates inhibited tumor angiogenesis and may also lead to enhanced activity of concurrently administered cancer therapeutics.